CaseyGerry attorneys are not currently accepting new clients for this case.
Pradaxa was the leading alternative treatment to warfarin for non-valvular atrial fibrillation, the most common type of heart rhythm abnormality. A safety announcement released in December 2011 by the U.S. Food and Drug Association (FDA) indicates that patients who use Pradaxa may be at risk for serious and sometimes fatal bleeding. As reported in Reuters the manufacturer of Pradaxa, Boehringer Ingelheim, related 260 fatal bleeding deaths to the drug as of November 2011.
A study recently performed by researchers at the Cleveland Clinic looked at more than thirty thousand patients and found that patients who are taking Pradaxa have an up to 33% increase risk of heart attack or acute coronary syndrome than those taking warfarin.
The FDA warns that discontinuing the use of Pradaxa can put patients at greater risk for a stroke. However, you are encouraged to seek professional care immediately if you notice the following symptoms: uncontrolled or unusual bleeding, suspicious bruising, blood in urine or stool, or coughing or vomiting blood.
CaseyGerry has a long history of drug litigation including representing those harmed against the makers of Pradaxa.